10q10k10q10k.net
KALA BIO, Inc.

KALA BIO, Inc.KALAEarnings & Financial Report

Nasdaq · Health Care · Pharmaceutical Preparations

KALA BIO, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative ophthalmology therapies. It has a pipeline of product candidates addressing both common and rare eye diseases, targeting unmet medical needs and serving patients and healthcare providers mainly across the United States.

Q4 2022Q3 2022Q2 2022Q1 2022

KALA Q4 FY2022 Key Financial Metrics

Revenue

$0

Gross Profit

N/A

Operating Profit

$-10.3M

Net Profit

$-12.8M

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

YoY Growth

N/A

EPS

$-7.63

KALA BIO, Inc. Q4 FY2022 Financial Summary

KALA BIO, Inc. reported revenue of $0 for Q4 FY2022, with a net profit of $-12.8M (up 73.0% YoY) (N/A margin).

Key Financial Metrics

Total Revenue$0
Net Profit$-12.8M
Gross MarginN/A
Operating MarginN/A
Report PeriodQ4 FY2022

KALA BIO, Inc. Annual Revenue by Year

KALA BIO, Inc. annual revenue history includes year-by-year totals (for example, 2022 revenue was $3.9M).

YearAnnual Revenue
2022$3.9M—

KALA BIO, Inc. Quarterly Revenue & Net Profit History

KALA BIO, Inc. results over the last 4 reported quarters, including revenue, net profit and year-over-year growth.

QuarterRevenueRevenue YoYNet ProfitNet Margin
Q4 FY2022$0—$-12.8MN/A
Q3 FY2022$420.0K-86.3%$29.1M6922.1%
Q2 FY2022$2.1M-31.2%$-28.1M-1338.6%
Q1 FY2022$1.4M-58.0%$-32.9M-2400.9%

Income Statement

Q1 2022Q2 2022Q3 2022Q4 2022
Revenue$1.4M$2.1M$420000$0
YoY Growth-58.0%-31.2%-86.3%N/A

Balance Sheet

Q1 2022Q2 2022Q3 2022Q4 2022
Assets$111.6M$85.0M$85.7M$86.8M
Liabilities$116.9M$116.5M$86.7M$67.8M
Equity$-5.3M$-31.6M$-968000$19.0M

Cash Flow

Q1 2022Q2 2022Q3 2022Q4 2022
Operating CF$-24.1M$-25.4M$-15.7M$-13.7M